Crossbow Therapeutics, led by drug development veteran Briggs Morrison, announced a $77 million Series B funding round to advance its T cell engager platform. The company has been actively conducting clinical trials over the past few quarters, following Morrison's philosophy of staying consistently in the clinic.
T cell engagers represent a promising approach in cancer immunotherapy, designed to redirect the body's T cells to attack tumor cells. Morrison, who has extensive experience in pharmaceutical development, founded Crossbow to focus specifically on this therapeutic modality.